Among the most promising non-incretin receptor targets are amylin (Amy) receptors (AMYRs), supported by data from phase I and phase II clinical trials showing efficacy of the long-acting amylin and calcitonin receptor agonist, cagrilinitide (Cagri), both as monotherapy 2,3 and in combination with the selective GLP-1R agonist, semaglutide 4,5
albicans In order to understand how GDH2 and GDH3 gene knockouts influence the metabolic changes associated with C
These can include nausea, vomiting, diarrhea, constipation, and bloating
Gap-PPI deficits in noise-exposed animals (defined as an index score exceeding the 95% CI) indicated that 38 of the 66 animals developed tinnitus, resulting in an overall incidence rate of 58%
Salvador, R., Moutinho, C